Academic Department of Urology of la Pitié-Salpêtrière Hospital, Assistance Publique - Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, France.
BJU Int. 2012 Dec;110(11 Pt B):E583-9. doi: 10.1111/j.1464-410X.2012.11298.x. Epub 2012 Jun 15.
What's known on the subject? and What does the study add? Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is an autosomal dominant multi-organ cancer syndrome. Upper urinary tract urothelial carcinomas belong to HNPCC-related tumours and rank third within this group after colorectal and endometrial cancer. However, many urologists are not aware of this association and it is presumed that some hereditary cancers are misclassified as sporadic and that their incidence is underestimated. Consequently, family members of patients with upper urinary tract urothelial carcinomas secondary to HNPCC may be denied appropriate surveillance and early detection. A significant proportion of patients (21.3%) with newly diagnosed upper urinary tract urothelial carcinomas may have underlying HNPCC. Demographic and epidemiological characteristics suggest different mechanisms of carcinogenesis among this population. Recognition of such potential is essential for appropriate clinical and genetic management of patients and family. In order to help to identify these patients, we propose a patient-specific checklist.
• To identify, based on previously described clinical criteria, hereditary upper urinary tract urothelial carcinomas (UUT-UCs) that are likely to be misclassified as sporadic although they may belong to the spectrum of hereditary non-polyposis colorectal cancer (HNPCC) associated cancers.
• We identified, using established clinical criteria, suspected hereditary UUT-UC among 1122 patients included in the French national database for UUT-UC. • Patients were considered at risk for hereditary status in the following situations: age at diagnosis <60 years with no previous history of bladder cancer; previous history of HNPCC-related cancer regardless of age; one first-degree relative with HNPCC-related cancer diagnosed before 50 years of age or two first-degree relatives diagnosed regardless of age.
• Overall, 239 patients (21.3%) were considered to be at risk of hereditary UUT-UC. • Compared with sporadic cases, hereditary cases are more likely to be female (P= 0.047) with less exposure to tobacco (P= 0.012) and occupational carcinogens (P= 0.037). A greater proportion of tumours were located in the renal pelvis (54.5% vs 48.4%; P= 0.026) and were lower grade (40% vs 30.1%; P= 0.015) in the hereditary cohort. • The overall, cancer-specific and recurrence-free survival rates were similar in both cohorts. • We propose a patient-specific risk identification tool.
• A significant proportion (21.3%) of patients with newly diagnosed UUT-UC may have underlying HNPCC as a cause. • Recognition of such potential and application of a patient-specific checklist upon diagnosis will allow identification and appropriate clinical and genetic management for patient and family.
• 根据先前描述的临床标准,确定可能被误诊为散发性的遗传性上尿路尿路上皮癌(UUT-UC),尽管它们可能属于遗传性非息肉病性结直肠癌(HNPCC)相关癌症的范畴。
• 我们使用已建立的临床标准,在法国全国 UUT-UC 数据库中纳入的 1122 名患者中确定了疑似遗传性 UUT-UC。
• 患者存在以下情况时被认为有遗传性疾病的风险:诊断时年龄<60 岁且无膀胱癌病史;有 HNPCC 相关癌症病史,无论年龄大小;一级亲属中有 HNPCC 相关癌症,诊断年龄<50 岁,或有两个一级亲属,无论年龄大小。
• 总体而言,239 名患者(21.3%)被认为有遗传性 UUT-UC 的风险。
• 与散发性病例相比,遗传性病例更可能为女性(P=0.047),吸烟(P=0.012)和职业性致癌剂暴露(P=0.037)较少。遗传性队列中更多的肿瘤位于肾盂(54.5%比 48.4%;P=0.026)且分级较低(40%比 30.1%;P=0.015)。
• 两组的总体生存率、癌症特异性生存率和无复发生存率相似。
• 我们提出了一种针对患者的风险识别工具。
• 新诊断的 UUT-UC 患者中有相当一部分(21.3%)可能存在 HNPCC 作为病因。
• 认识到这种潜在情况,并在诊断时应用患者特异性检查表,将有助于识别患者,并对患者及其家属进行适当的临床和遗传管理。